Validación y aplicación del puntaje Globorisk-LAC en una cohorte de pacientes del noroccidente de Colombia
Contenido principal del artículo
Keywords
Riesgo Cardiovascular, Modelos de Predicción, Validación Interna, Cohorte, Enfermedades Cardiovasculares
Resumen
Objetivos: Validar internamente el modelo Globorisk-LAC para la predicción del riesgo cardiovascular a 10 años en una cohorte del noroccidente colombiano, adaptándolo a las características epidemiológicas propias de América Latina y el Caribe. Metodología: Se emplearon datos provenientes de estudios de cohorte prospectivos de la región. Se desarrollaron modelos de predicción —uno basado en laboratorio y otro para consultorio— utilizando regresiones de riesgos proporcionales de Cox, con la edad como escala temporal. Ambos modelos fueron recalibrados según edad y sexo. La discriminación se evaluó mediante la estadística C de Harrell y la calibración mediante regresión lineal entre el riesgo predicho y el observado. Resultados: Globorisk-LAC mostró una adecuada capacidad discriminativa (estadística C: 0,79; IC95%: 0,69–0,89) y un buen desempeño en calibración (pendiente: 0,852). La sensibilidad y especificidad variaron según el umbral de riesgo (10% y 20%). Los modelos de laboratorio y consultorio —este último con predictores fácilmente disponibles como presión arterial sistólica e índice de masa corporal— demostraron buena aplicabilidad en entornos de bajos recursos. En comparación con modelos globales recalibrados, Globorisk-LAC presentó menor subestimación del riesgo, particularmente en mujeres. Asimismo, se identificaron diferencias de riesgo por sexo y se incorporaron patrones epidemiológicos actuales de factores de riesgo cardiovascular.
Conclusiones: Globorisk-LAC constituye una herramienta válida y prometedora para fortalecer la prevención primaria, promover la equidad en salud y contribuir al cumplimiento de los Objetivos de Desarrollo Sostenible. Se recomienda realizar estudios de validación externa en otras poblaciones latinoamericanas para confirmar su utilidad clínica.
Citas
2. Atun R, de Andrade LO, Almeida G, et al. Health-system reform and universal health coverage in Latin America. Lancet. 2015;385:1230–1247.
3. Prabhakaran D, Anand S, Watkins D, et al. Cardiovascular, respiratory, and related disorders: key messages from disease control priorities, 3rd edition. Lancet. 2018;391:1224–1236.
4. Karmali KN, Persell SD, Perel P, et al. Risk scoring for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2017;3:CD006887.
5. Lim SS, Gaziano TA, Gakidou E, et al. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet. 2007;370:2054–2062.
6. Damen JA, Hooft L, Schuit E, et al. Prediction models for cardiovascular disease risk in the general population: systematic review. BMJ. 2016;353:i2416.
7. Hajifathalian K, Ueda P, Lu Y, et al. A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys. Lancet Diabetes Endocrinol. 2015;3:339–355.
8. Ueda P, Woodward M, Lu Y, et al. Laboratory-based and office-based risk scores and charts to predict 10-year risk of cardiovascular disease in 182 countries: a pooled analysis of prospective cohorts and health surveys. Lancet Diabetes Endocrinol. 2017;5:196–213.
9. WHO CVD Risk Chart Working Group. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Health. 2019;7:e1332–e1345.
10. Singh GM, Danaei G, Farzadfar F, et al. The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis. PLoS One. 2013;8:e65174.
11. Woodward M, Huxley H, Lam TH, et al. A comparison of the associations between risk factors and cardiovascular disease in Asia and Australasia. Eur J Cardiovasc Prev Rehabil. 2005;12:484–491.
12. Carrillo-Larco RM, Altez-Fernandez C, Pacheco-Barrios N, et al. Cardiovascular disease prognostic models in Latin America and the Caribbean: a systematic review. Glob Heart. 2019;14:81–93.
13. Cohorts Consortium of Latin America and the Caribbean (CC-LAC). Cohort profile: the Cohorts Consortium of Latin America and the Caribbean (CC-LAC). Int J Epidemiol. 2020;49:1432–1433.
14. Collins GS, Reitsma JB, Altman DG, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med. 2015;162:55–63.
15. Muñoz VOM, Ruiz Morales ÁJ, Mariño Correa A, et al. Concordancia entre los modelos SCORE y Framingham y las ecuaciones AHA/ACC como evaluadores de riesgo cardiovascular. Rev Colomb Cardiol. 2017;24:110–116.
16. Blümel JE, Carrillo-Larco RM, Vallejo MS, et al. Multimorbidity in a cohort of middle-aged women: risk factors and disease clustering. Maturitas. 2020;137:45–49.
17. Tartaglione JE, Grazioli GC, Sarmiento MP, et al. Eventos cardiovasculares en una población cerrada: seguimiento a 10 años. Rev Fed Arg Cardiol. 2013;42:106–113.
18. Lajous M, Ortiz-Panozo E, Monge A, et al. Cohort profile: the Mexican teachers' cohort (MTC). Int J Epidemiol. 2017;46:e10.
19. Denova-Gutiérrez E, Flores YN, Gallegos-Carrillo K, et al. Health workers cohort study: methods and study design. Salud Publica Mex. 2016;58:708–716.
20. Huxley RR, Woodward M. Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. Lancet. 2011;378:1297–1305.
21. Peters SA, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts. Lancet. 2014;383:1973–1980.
22. Lawes CM, Bennett DA, Parag V, et al. Blood pressure indices and cardiovascular disease in the Asia Pacific region: a pooled analysis. Hypertension. 2003;42:69–75.
23. Lewington S, Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370:1829–1839.
24. Farzadfar F, Finucane MM, Danaei G, et al. National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies. Lancet. 2011;377:578–586.
25. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet. 2017;389:37–55.
26. NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet. 2016;387:1377–1396.
27. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387:1513–1530.
28. Ng M, Freeman MK, Fleming TD, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980–2012. JAMA. 2014;311:183–192.
29. Adler AI, Stevens RJ, Neil A, et al. UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care. 2002;25:894–899.
30. Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003.
